Abstract
This paper reviews the history and pre-clinical development of idebenone and summarises the results of clinical studies, published from 1999 to 2008, on the use of idebenone in the treatment of patients with Friedreich ataxia (FRDA). As a benzoquinone that can undergo reversible redox reactions, idebenone influences the electron balance in mitochondria. In vitro studies have shown that it acts both as an anti-oxidant, preventing damage to the mitochondrial membrane, and, more importantly, as an electron carrier, supporting mitochondrial function and adenosine triphosphate (ATP) production. In clinical studies, idebenone has been well tolerated by patients with various pathological conditions. The most common adverse events have been gastrointestinal effects of mild to moderate severity. No neurotoxic or adverse cardiac reactions have been reported in pre-clinical or clinical studies. The good safety profile of idebenone is supported by large clinical trials in Alzheimer’s disease and by post-marketing surveillance. Phase 1 studies demonstrated the safety and tolerability of idebenone at relatively high doses (up to 60 mg/kg/day). Results from 11 clinical studies (randomised, controlled, and open-label trials), involving a total of about 200 patients, provide evidence of improvement in both cardiac hypertrophy and neurological symptoms among patients with FRDA treated with idebenone.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
McGuffin M, Young AL (2004) Premarketnotifications of new dietaryingredients – a ten year review. FoodDrug Law J 59:233
Okamoto K, Matsumoto M, WatanabeM, Kawada M, Imamoto T, Imada I(1985) Effects of 6-(ω-substitutedalkyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinones and related compoundson mitochondrial succinateand reduced nicotinamide adeninedinucleotide oxidase systems. ChemPharm Bull 33:3745–3755
Suno M, Nagaoka A (1984) Inhibitionof lipid peroxidation by a novel compound,idebenone (CV-2619). Jpn JPharmacol 35:196–198
Suno M, Nagaoka A (1984) Inhibitionof lipid peroxidation by a novel compound(CV-2619) in brain mitochondriaand mode of action of the inhibition.Biochem Biophys Res Comm 125:1046–1052
Suno M, Nagaoka A (1985) Inhibitionof mitochondrial swelling and lipidperoxidation by a novel compound,idebenone (CV-2619). Jpn PharmacolTher 13:673–678
Sugiyama Y, Fujita T (1985) Stimulationof the respiratory and phosphorylatingactivities in rat brain mitochondriaby idebenone (CV-2619), a newagent improving cerebral metabolism.FEBS Lett 184:48–51
Sugiyama Y, Fujita T, Matsumoto M,Okamoto K, Imada I (1985) Effects ofidebenone (CV-2619) and its metaboliteson respiratory activity and lipidperoxidation in brain mitochondriafrom rats and dogs. J Pharmacobio-Dyn 8:1006–1017
Esposti MD, Ngo A, Ghelli A, Benelli B,Carelli V, McLennan H, Linnane AW(1996) The interaction of Q analogs,particularly hydroxydecyl benzoquinone(idebenone), with the respiratorycomplexes of heart mitochondria. ArchBiochem Biophys 330:395–400
James AM, Cocheme HM, Smith R,Murphy MP (2005) Interactions ofmitochondria-targeted and untargetedubiquinones with the mitochondrialrespiratory chain and reactive oxygenspecies. J Biol Chem 280:21295–21312
Di Prospero NA, Sumner CJ, PenzakSR, Ravina B, Fischbeck KH, Taylor JP(2007) Safety, tolerability, and pharmacokineticsof high-dose idebenone inpatients with Friedreich ataxia. ArchNeurol 64:803–808
Schulz JB, Dehmer T, Schöls L, MendeH, Hardt C, Vorgerd M, Bürk K, MatsonW, Dichgans J, Beal MF, Bogdonav MB(2000) Oxidative stress in patients withFriedreich’s ataxia. Neurology 55:1719–1721
Rustin P, von Kleist-Retzow JC,Chantrel-Groussard K, Sidi D, MunnichA, Rotig A (1999) Effect of idebenoneon cardiomyopathy in Friedreich’sataxia: a preliminary study. Lancet 354:477–479
Hausse AO, Aggoun Y, Bonnet D, Sidi D,Munnich A, Rötig A, Rustin P (2002)Idebenone and reduced cardiac hypertrophyin Friedreich’s ataxia. Heart 87:346–349
Mariotti C, Solari A, Torta D, Marano L,Fiorentini C, Di Donato S (2003)Idebenone treatment in Friedreichpatients: one-year-long randomisedplacebo-controlled trial. Neurology60:1676–1679
Buyse G, Mertens L, Di Salvo G,Matthijs I, Wiedemann F, Eyskens B,Goossens W, Goemans N, SutherlandGR, Van Hove JL (2003) Idebenonetreatment in Friedreich’s ataxia: neurological,cardiac and biochemical monitoring.Neurology 60:1679–1681
Rustin P, Bonnet D, Roetig A, MunnichA, Sidi D (2004) Idebenone treatmentin Friedreich patients. Neurology 62:524–525
Schöls L, Vorgerd M, Schillings M,Skipka G, Zange J (2001) Idebenone inpatients with Friedreich’s ataxia.Neurosci Lett 306:169–172
Pineda M, Arpa J, Montero R, Aracil A,Domínguez F, Galván M, Mas A,Martorell L, Sierra C, Brandi N, García-Arumí E, Rissech M, Velasco D, CostaJA, Artuch R (2008) Idebenone treatmentin paediatric and adult patientswith Friedreich ataxia: long-termfollow up. Eur J Paediat Neurol 12:470–475
Ribaï P, Pousset F, Tanguy ML, Rivaud-Pechoux S, LeBer I, Gasparini F,Charles P, Béraud AS, Schmitt M,Koenig M, Mallet A, Brice A, Dürr A(2007) Neurological, cardiological, andoculomotor progression in 104 patientswith Friedreich ataxia duringlong-term follow-up. Arch Neurol 64:558–564
Artuch R, Aracil A, Mas A, Colomé C,Rissech M, Monrós E, Pineda M (2002)Friedreich’s ataxia: idebenone treatmentin early stage patients. Neuropediatrics33:130–193
Arnold P, Boulat O, Maire R, Kuntzer T(2006) Expanding view of phenotypeand oxidative stress in Friedreichataxia patients with and withoutidebenone. Schweizer Archiv fürNeurology und Psychiatry 157:169–176
Di Prospero NA, Baker A, Jeffries N,Fischbeck KH (2007) Neurologicaleffects of high-dose idebenone inpatients with Friedreich’s ataxia:a randomised, placebo-controlled trial.Lancet Neurol 6:878–886
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meier, T., Buyse, G. Idebenone: An emerging therapy for Friedreich ataxia. J Neurol 256 (Suppl 1), 25–30 (2009). https://doi.org/10.1007/s00415-009-1005-0
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-1005-0